The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

McCann KJ, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P, Kerr JP, Malykh VB, Jenner MW, Orchard KH, Stevenson FK, Ottensmeier CH. Cancer Immunol Immunother. 2015 Aug;64(8):1021-32. doi: 10.1007/s00262-015-1703-7. Epub 2015 May 16. PMID: 25982371 [PubMed - in process] Free PMC Article READ MORE

Posted: August 20, 2015

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. PMID: 26035255 [PubMed - in process] READ MORE

Posted: August 20, 2015

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink PP, de Bruin G, Kisselev AF, Overkleeft H, Driessen C. Cancer Chemother Pharmacol. 2015 Aug;76(2):383-96. doi: 10.1007/s00280-015-2801-0. Epub 2015 Jun 23. PMID: 26099967 [PubMed - in process] READ MORE

Posted: August 20, 2015

Page 49 of 87« First...102030...4748495051...607080...Last »